UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 9, 2021
AVITA Medical, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39059 | 85-1021707 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| 28159 Avenue Stanford, Suite 220, Valencia, CA 91355 | 661.367.9170 | |||
| (Address of principal executive offices, including Zip Code) |
(Registrant’s telephone number, including area code) | |||
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common Stock, par value $0.0001 per share | RCEL | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On April 9, 2021, the board of directors (the “Board”) of AVITA Medical, Inc. (the “Company”) appointed Jeremy Curnock Cook to serve as an Independent Director on the Audit Committee of the Board, effective April 9, 2021. Mr. Curnock Cook’s appointment to the Audit Committee was made pursuant to the Board’s determination that Mr. Curnock Cook satisfies all applicable requirements to serve on the Audit Committee, including without limitation, the applicable requirements of the Securities Exchange Act of 1934, as amended.
Following Mr. Curnock Cook’s appointment to the Audit Committee, the current committees of the Board and their respective members are as follows:
| Director |
Independent | Compensation Committee |
Audit Committee |
Nomination Committee | ||||
| Lou Panaccio |
☒ | Member | ||||||
| Jeremy Curnock Cook |
☒ | Member | Member | Member | ||||
| Louis Drapeau |
☒ | Member | Chair | Member | ||||
| Professor Suzanne Crow |
☒ | Chair | Chair |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 12, 2021
| AVITA MEDICAL, INC. | ||
| By: | /s/ Donna Shiroma | |
| Name: | Donna Shiroma | |
| Title: | General Counsel | |